Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients
- PMID: 17872904
- DOI: 10.1093/hmg/ddm265
Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients
Abstract
Polymorphisms in the MBL2 gene, which affect the structure and influence on the serum concentration of mannose-binding lectin (MBL), are associated with inflammatory and infectious conditions. The importance of MBL2 polymorphisms on outcome in critical ill patients is unclear. Five hundred and thirty-two consecutive critically ill patients admitted to an intensive care unit (ICU) were included over a period of 18 months. Five hundred and thirty-three individuals served as controls. Vital status was obtained 15.5 months after the last patient was included. MBL2 polymorphisms were determined by a PCR-based assay. Homozygosity for MBL2 variant alleles (O/O) causing MBL structural defects was associated with the highest adjusted mortality rate followed by homozygosity for the normal MBL2 allele (A/A) encoding high MBL levels, whereas heterozygous A/O patients had the most favourable outcome (P = 0.015). MBL2 alleles were not associated with death in ICU (n = 166, P = 0.7), but the association appeared soon after discharge from ICU (n = 366): hazard ratio (HR) for O/O using A/A as reference was 1.33 (95% CI: 0.8-2.2) and for A/O it was 0.62 (95% CI: 0.4-0.8) respectively (P = 0.0045) at completion. No difference in MBL2 frequency was observed between patients and controls at baseline, and between patients classified as having sepsis or not. However, patients with the MBL2 O/O genotype had an increased frequency of Gram-positive bacterial infection (P = 0.01). Heterozygosity for MBL2 alleles confers a protective effect whereas homozygosity is associated with the worst outcome soon after discharge from ICU. This may be an example of heterosis.
Similar articles
-
Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults.J Allergy Clin Immunol. 2008 Aug;122(2):368-74, 374.e1-2. doi: 10.1016/j.jaci.2008.05.037. Epub 2008 Jun 25. J Allergy Clin Immunol. 2008. PMID: 18582923
-
Gene-environment interaction between MBL2 genotype and smoking, and the risk of gram-positive bacteraemia.Scand J Immunol. 2008 Oct;68(4):438-44. doi: 10.1111/j.1365-3083.2008.02149.x. Scand J Immunol. 2008. PMID: 18782274
-
Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation.Liver Transpl. 2009 Oct;15(10):1217-24. doi: 10.1002/lt.21834. Liver Transpl. 2009. PMID: 19790141
-
Mannose-binding lectin: biology and clinical implications.Intern Med J. 2005 Sep;35(9):548-55. doi: 10.1111/j.1445-5994.2005.00908.x. Intern Med J. 2005. PMID: 16105157 Review.
-
Mannose-binding lectin genetics: from A to Z.Biochem Soc Trans. 2008 Dec;36(Pt 6):1461-6. doi: 10.1042/BST0361461. Biochem Soc Trans. 2008. PMID: 19021576 Review.
Cited by
-
Mannose-binding lectin polymorphisms and the risk of sepsis: evidence from a meta-analysis.Epidemiol Infect. 2014 Oct;142(10):2195-206. doi: 10.1017/S0950268813003361. Epub 2014 Jan 7. Epidemiol Infect. 2014. PMID: 24398289 Free PMC article.
-
The emergence of human-evolutionary medical genomics.Evol Appl. 2011 Mar;4(2):292-314. doi: 10.1111/j.1752-4571.2010.00156.x. Epub 2010 Oct 12. Evol Appl. 2011. PMID: 25567974 Free PMC article.
-
Tackling COVID-19 infection through complement-targeted immunotherapy.Br J Pharmacol. 2021 Jul;178(14):2832-2848. doi: 10.1111/bph.15187. Epub 2020 Jul 27. Br J Pharmacol. 2021. PMID: 32643798 Free PMC article. Review.
-
Low levels of mannose-binding lectin confers protection against tuberculosis in Turkish children.Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1165-9. doi: 10.1007/s10096-008-0573-8. Epub 2008 Jul 9. Eur J Clin Microbiol Infect Dis. 2008. PMID: 18612667
-
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.Pharmacol Rev. 2021 Apr;73(2):792-827. doi: 10.1124/pharmrev.120.000072. Pharmacol Rev. 2021. PMID: 33687995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous